Alkermes (ALKS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
Annual general meeting scheduled for May 20, 2026, at the company's Dublin offices.
Shareholders as of March 13, 2026, are eligible to vote on key proposals.
Proxy materials, including the notice and annual report, are available online and by request.
Voting matters and shareholder proposals
Election of nine directors for a one-year term until the 2027 annual meeting.
Advisory vote on executive compensation (say-on-pay).
Ratification of PricewaterhouseCoopers LLP as independent auditor and authorization for the Audit and Risk Committee to set remuneration.
Approval of amendments to the 2018 Stock Option and Incentive Plan.
Renewal of Board authority to allot and issue shares and to disapply statutory pre-emption rights under Irish law.
Board of directors and corporate governance
Board recommends voting for all director nominees and all proposals.
Shareholders may appoint proxies, including individuals not specified on the proxy card.
Latest events from Alkermes
- Strong 2025 performance, governance enhancements, and key proposals mark this annual proxy.ALKS
Proxy filing6 Apr 2026 - Annual meeting to vote on directors, executive pay, auditor, equity plan, and share issuance.ALKS
Proxy filing27 Mar 2026 - Orexin agonists advance with flexible dosing, durable efficacy, and new indications in sleep and fatigue.ALKS
Stifel 2026 Virtual CNS Forum17 Mar 2026 - Major advances in sleep medicine and orexin pipeline drive growth and future opportunities.ALKS
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - 2026 outlook projects strong revenue growth, LUMRYZ integration, and pipeline advancement.ALKS
Q4 202525 Feb 2026 - Orexin program advances in phase 2, targeting narcolepsy and broader CNS disorders.ALKS
7th Annual Evercore ISI HealthCONx Healthcare Conference3 Feb 2026 - Proprietary product sales rose 16% year-over-year, driving robust Q2 profitability.ALKS
Q2 20243 Feb 2026 - Focused neuroscience strategy, robust orexin data, and share buybacks drive growth outlook.ALKS
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Orexin agonists demonstrate strong efficacy and safety, with commercial momentum building in 2024.ALKS
Jefferies 2024 Global Healthcare Conference1 Feb 2026